School of Medicine
Showing 2,601-2,700 of 4,255 Results
-
Jonathan N. Myers
Clinical Professor (Affiliated), Medicine - Med/Cardiovascular Medicine
BioDr. Myers is a Health Research Scientist at the Palo Alto VA Health Care System; a Clinical Professor at Stanford University (Affiliated), and a Senior Research Career Scientist Award recipient through the VA Rehabilitation Research and Development Program. His research has focused on primary and secondary prevention, and the clinical applications of exercise testing and rehabilitation in patients with cardiovascular disease and other chronic conditions. He has a lengthy history of studying the epidemiology of cardiopulmonary exercise test responses, physical activity patterns, and other lifestyle factors and their relation to health outcomes. He manages the Veterans Exercise Testing Study (VETS), an ongoing, prospective evaluation of Veteran subjects referred for exercise testing for clinical reasons, designed to address exercise test, clinical, and lifestyle factors and their association with health outcomes.
He earned his bachelor’s degree from the University of California, Santa Barbara, his master's degree from San Diego State University, and his doctorate from the University of Southern California. He has been a board member for many organizations including the American Heart Association (AHA), the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR), and the American College of Sports Medicine (ACSM), and serves on the editorial board for 9 journals. He is a recipient of the Michael Pollock Established Investigator Award through the AACVPR, a recipient of the Steven N Blair Award for excellence in physical activity research from the AHA Council on Epidemiology and Prevention and is the 2022 recipient of the American College of Sports Medicine Citation Award. He is a fellow of the AACVPR, ACSM, American College of Cardiology, and the AHA, and has authored and co-authored guidelines on exercise testing and rehabilitation for each of these organizations, including the 2021 editions of the ACSM and AACVPR guidelines. -
Behzad Naderalvojoud
Biostatistician 2, Computational Medicine
BioBehzad Naderalvojoud is a biomedical informatics scientist at the Stanford Center for Biomedical Informatics Research. He received his Ph.D. degree in computer science at Hacettepe University, Turkey, in 2020. He is immersed in the fields of machine learning, deep learning, natural language understanding, and Big data analytics and works on health knowledge discovery platforms that transfer Big health data from volume-based to value-based by generating relational knowledge leading to innovative treatments, predictive therapeutic outcomes, and early diagnosis. He was the leader of many industrial AI projects in the fields of healthcare intelligence and information management in the Eureka cluster programs.
Dr. Naderalvojoud has published several papers in the field of natural language understanding by working on word sense disambiguation, sentiment analysis, neural word embeddings, and deep learning models through national and international projects.
He is currently working on the funded NLM grant project "Advancing Knowledge Discovery for Postoperative Pain Management" under the supervision of Dr. Tina Hernandez-Boussard. He develops descriptive, predictive, and analytical tools using OMOP CDM for postoperative pain research to facilitate timely generation of evidence across multiple populations and settings. -
Ronjon Nag, OBE PhD MS BSc FIET FRSM CEng
Adjunct Professor, Genetics
BioRonjon Nag is an inventor, teacher and entrepreneur. He is an Adjunct Professor in Genetics at the Stanford School of Medicine, becoming a Stanford Distinguished Careers Institute Fellow in 2016. He teaches AI, Genes, Ethics, Longevity Science and Venture Capital. He is a founder and advisor/board member of multiple start-ups and President of the R42 Group, a venture capital firm which invests in, and creates, AI and Longevity companies. As an AI pioneer of smartphones and app stores, his companies have been sold to Apple, BlackBerry, and Motorola. More recently he has worked on the intersection of AI and Biology. He has been awarded the IET Mountbatten Medal by the Institution of Engineering and Technology, the 2021 IEEE-SCV Outstanding Engineer Award, the $1m Verizon Powerful Answers Award, the 2023 COGX AI Lifetime Achievement Award, the 2023 MIT Great Dome Award, and was the 2024 Inductee in the Silicon Valley Engineering Hall of Fame. Professor Nag has a Ph.D from Cambridge, an M.S from Massachusetts Institute of Technology and a B.Sc. from Birmingham in the UK. He has numerous interests in the intersection of AI and Healthcare including being CEO of Agemica.ai working on creating a vaccine for aging. In 2026 he was awarded Officer of the Order of the British Empire (OBE) in King Charles III Birthday Honors. He is a Fellow of the Royal Society of Medicine.
He has many firsts including:
Firsts:
• First laptop with speech recognition built-in (with Apricot, 1984)
• First selling cursive handwriting recognition (with Lexicus, 1991)
• First speech recognition phones (with Lexicus/Motorola, 1996)
• First large-vocabulary Chinese speech recognition (with Lexicus/Motorola, 1996)
• First Chinese predictive text system on a phone (Lexicus/Motorola, 1997)
• First predictive text systems in 40 languages on Motorola phones, (Lexicus/Motorola, 1997)
• First touch screen mobile phone with handwriting recognition (Lexicus/Motorola, 1999)
• First combined mobile search engine and directory (with Cellmania, 2000)
• First private label downloadable operator billable apps store (Cellmania, 2000)
• First BlackBerry Operator Billing apps store (Cellmania,2010)
• First Neural Network Artificial Intelligence System in the Cloud (Ersatz Labs, 2014)
• First Throwable 360 Ball Camera (Bounce Imaging, 2015)
• First Android powered smart light switch (Brightswitch 2017)
• First blood pressure watch with temperature and pulse oximetry add-ons for Back to Work Covid Kit (GTCardio 2019)
• First no code AI life sciences app store (Superbio.ai 2022)
• First proposal for an aging vaccine (Agemica 2023) -
Ramesh Nair
Director of Bioinformatics, SCGPM, Genetics
Current Role at StanfordDirector, Bioinformatics
Stanford Center for Genomics and Personalized Medicine (SCGPM)
Bioinformatics-as-a-Service (BaaS)
Genetics Bioinformatics Service Center (GBSC)
Diabetes Genomics Analysis Core (DGAC)
Stanford University School of Medicine -
Michitaka Nakano
Basic Life Research Scientist, Medicine - Med/Hematology
BioI am a MD/PhD postdoctoral fellow and medical oncologist with a long-standing interest in translational cancer research. My long-term goal is to be a lab-based physician-scientist and independent academic researcher, translating basic cancer research, and mentoring next-generation scientists. My thesis work in Japan focused on cancer stem cell equilibrium by uniquely applying organoid culture as a method to elucidate cancer stem cell dynamics, which was awarded in Japanese Cancer Association. Along with the development of the field represented by success in T cell checkpoint, my interest gradually shifted to immune oncology while I examined numerous numbers of cancer patients as a medical oncology fellow. My postdoctoral fellowship at Calvin Kuo Lab in Stanford (2019-present) focuses on tumor immune microenvironment. Kuo lab developed a unique 3D air-liquid interface (ALI) organoid system that cultures tumors while preserving their endogenous infiltrating immune cells (T,B ,NK, Myeloid cells). My postdoctoral work will prove the significance of organoids as a translational tool to discover tumor-immune interaction by novel checkpoint inhibitors for immune cells, which can be broadly applicable to basic cancer biology, precision medicine, therapeutics validation and biomarker discovery.
-
Yusuke Nakauchi, MD, PhD
Basic Life Research Scientist, Stem Cell Bio Regenerative Med Institute
BioDr. Yusuke Nakauchi is a scientist specializing in stem cell biology, focusing on normal hematopoietic stem cells (HSCs), pre-leukemic HSCs, and leukemia stem cells (LSCs).
From 2005 to 2014, he trained and practiced as a clinical hematologist in Japan, where he witnessed allogeneic hematopoietic stem cell transplantation (HSCT) cure patients with otherwise fatal blood cancers—and saw many others suffer long-term complications from graft-versus-host disease (GVHD). Having saved many patients, yet lost others he could not save, he became convinced that overcoming the limitations of leukemia treatment would require a deeper understanding of both normal HSCs and the LSCs responsible for relapse.
This conviction led him to pursue basic research. In 2010, he began his PhD in the laboratory of Professor Hiromitsu Nakauchi at the University of Tokyo, where he developed allele-specific anti-HLA monoclonal antibodies as a novel therapeutic strategy for GVHD—the first work to demonstrate that anti-HLA antibodies could be used therapeutically in HLA-mismatched transplantation. This research also revealed the importance of detailed chimerism analysis for understanding early post-transplant changes in a patient's blood and HSCs, a theme he later continued at Stanford. As a graduate student, he also contributed to work on iPSC-derived T cell therapy and a large-scale single-cell study of HSC aging.
In 2014, building on this clinical and research foundation, Dr. Nakauchi joined Professor Ravindra Majeti's laboratory at Stanford University as a postdoctoral fellow. His research there centered on TET2, one of the most frequently mutated genes in acute myeloid leukemia (AML) and clonal hematopoiesis. Using CRISPR/Cas9 editing in human hematopoietic stem and progenitor cells, he developed a tractable model of TET2-mutant pre-leukemia, showing how TET2 loss reshapes epigenetic and transcriptional programs to drive clonal expansion—and how azacitidine plus vitamin C could restore normal function in TET2-mutant cells. His work now extends to antibody-based approaches to GVHD, single-cell analysis of CMML stem cells, and advanced in vivo mouse models, pursued through collaborations across and beyond Stanford.
Dr. Nakauchi's long-term goal is to bring personalized medicine to patients with AML and other blood cancers, believing that comparing normal HSCs, pre-leukemic HSCs, and LSCs at single-cell resolution is key to understanding—and ultimately preventing—leukemia. Drawing on years as a clinician who witnessed many patients lose their lives to AML, he is driven by the conviction that discoveries in stem cell biology will one day help cure and prevent the disease. -
Arutselvan Natarajan
Senior Research Scientist - Basic Life, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordSenior Scientist
-
Michael Nedelman
Adjunct Lecturer, Medicine - Primary Care and Population Health
BioDr. Michael Nedelman is a global health and media specialist who co-founded the Stanford Health Media Fellowship at the School of Medicine. He also works in global health tech with an organization called Maisha Meds, which uses technology to expand healthcare access in sub-Saharan Africa. Previously, Dr. Nedelman covered health and medicine as a journalist for CNN, earning an Emmy nomination for the network's acclaimed reporting on the Covid-19 pandemic. As producer for the inimitable Dr. Sanjay Gupta, he was part of a team known for excellent reporting and storytelling — also winning a Cronkite Award for tackling misinformation during the pandemic. Before CNN, he was a digital producer for the ABC News Medical Unit, worked on public health campaigns at the World Health Organization in New Delhi, and trained at the Stanford Journalism Program as part of the university's Global Health Media Fellowship. He received his MD from Stanford and did his undergraduate work in film at Yale.
-
Margaret Jane Neff
Clinical Associate Professor (Affiliated), Medicine - Med/Pulmonary, Allergy & Critical Care Medicine
Medical Director--Vapahcs Medical Surgical Icu, Medicine - Med/Pulmonary, Allergy & Critical Care MedicineBioMy training is in Pulmonary & Critical Care Medicine, and I've been blessed to be part of the care of many patients and their families. My clinical research interests have been in the field of critical care medicine and ARDS, a type of acute respiratory failure seen commonly in patients with severe injuries or illnesses. I also have a particular interest in evaluating and improving processes for care. Issues like standardizing processes to improve reliability, improving safety of handoffs, and exploring ways to teach "roundsmanship" (the process of discussing patients' care with a group of providers) are current interests of mine.
The future of medical care depends on training the next generation of providers, and I'm thankful to be part of training this next generation. Teaching at the bedside or in formal classroom settings gives me great joy and satisfaction. I'm delighted to work with a great, multidisciplinary team of physicians, nurse practitioners, nurses, respiratory therapists, and pharmacists. I add to that team our patients and families, for it truly takes a team to provide care that is both excellent and compassionate. -
Hesam N. Motlagh
Adjunct Professor, Structural Biology
BioHesam is passionate about translating basic science discoveries into products that have a significant impact on society. He is Chief of Staff at Khosla Ventures where he works with Vinod Khosla on strategic projects for the firm and advises portfolio companies on fundraising, product, business development, marketing, and general strategy.
Currently, Hesam is an Adjunct Professor in the Department of Structural Biology at Stanford Medicine and a Fellow in The Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise where he is editor of the Studies in Applied Finance. Previously, he worked on financial and corporate strategy at Seer Biosciences and was a Pear Fellow at Pear VC. Before Seer, he was a quant at an investment management firm after being a molecular and computational biophysicist for almost a decade.
Hesam has many peer-reviewed publications including a review article that was highlighted on the cover of Nature. He completed his MBA at Stanford Graduate School of Business, obtained his PhD from the Program in Molecular Biophysics at The Johns Hopkins University under the supervision of Vincent Hilser, and obtained his undergraduate degrees from Miami University in Oxford, Ohio. -
Gernot Neumayer
Sr Res Scientist-Basic Life, Stem Cell Bio Regenerative Med Institute
Current Role at StanfordSenior Scientist
